Success Stories: North America Immigration Law Group Helps an Indian Biologist in Cardiovascular Biology Obtain EB-1A Approval, Despite Initial Refusal by USCIS
Client’s Testimonial:
“Thanks a lot for your help. In fact GREAT help.”
On November 24th, 2021, we received another EB-1A (Alien of Extraordinary Ability) approval for a Biologist in the Field of Cardiovascular Biology (Approval Notice).
General Field: Cardiovascular Biology
Position at the Time of Case Filing: Biologist
Country of Origin: India
State of Residence at the Time of Filing: Maryland
Approval Notice Date: November 24th, 2021
Processing Time: 7 months, 8 days
Case Summary:
A petitioner may be eligible for an employment-based, first-preference visa if they are a noncitizen of extraordinary ability, are an outstanding professor or researcher, or are a certain multinational executive or manager. The EB1-A (Alien of Extraordinary Ability) visa type thus requires one to demonstrate extraordinary ability in the sciences, arts, education, business, or athletics through sustained national or international acclaim.
Our EB1-A client from India is a leading cardiovascular disease prevention and treatment expert in cardiovascular biology. He has achieved a consistent and notable record of success and influence in this area of study and is especially well-known for his research on the relationship between quercetin and monocyte chemoattractant protein-1 gene expression in glucose-primed aortic endothelial cells. This meant that the years he has spent working in the area has led him to be recognized as an extraordinary researcher and an authority in the field.
This was evident to us because the field has recognized his authority by inviting him to review and evaluate the work of his peers no fewer than 39 times. He has also actively engaged his peers in the field of cardiovascular biology by authoring and co-authoring 16 peer-reviewed journal articles and 1 scientific book chapter that have been published in international journals. At the same time, due to its great applicability in the field, his research in cardiovascular biology has been cited 213 times in other peer-reviewed journal articles according to Google Scholar.
Our team made sure that these facts were corroborated by letters of recommendation from other experts in the field, two of which are quoted below:
“Given the widespread threat posed by atherosclerosis and heart disease, it is easy to see that [client’s] research has a great value with respect to treating these conditions in the United States, where heart disease remains the number one killer.”
“[The client] is an exemplary cardiovascular biologist whose work has been critical to the interests of the United States. His studies of the mechanochemistry of L-selectin and its mutations, for instance, have been integral to reaching a thorough understanding of the inner mechanisms and genetic risk factors that contribute to cardiovascular diseases. As the majority of [client's] work revolves around uncovering the cellular and molecular mechanisms of these diseases and subsequently designing strategies to prevent their initiation and progression, he is a standout researcher in his field.”
Thus, the success of his EB1-A case was welcome news for all of us. We thank him for his continuing trust in our firm and for retaining us to work on his NIW case which also received approval with our diligent work.